

Review Article

# Innovative Insights and Multidimensional Strategies for Addressing Sexually Transmitted Diseases: A Review

Priyanka Malaiyappan<sup>1</sup>, Shilpa Prasad<sup>2</sup>, Vettrivel Arul<sup>3</sup>, Keerthana Babudevaraj<sup>4</sup>, Janet Cynthia Selvaraj<sup>5</sup>

<sup>1</sup>Manam Healthcare Hospital, Tirupur, Tamil Nadu, India

<sup>2,3</sup>Vinayaka Mission's Homoeopathic Medical College & Hospital, Vinayaka Mission's Research Foundation DU, Salem, Tamil Nadu, India

<sup>4</sup>Excel Homoeopathy Medical College, Namakkal, Tamil Nadu, Tamil Nadu Dr M G R Medical University, Chennai, India

<sup>5</sup>Sri Sairam Homoeopathy Medical College & Research Centre, Chennai Affiliated to The Tamil Nadu Dr M G R Medical University, Chennai, India

DOI: <https://doi.org/10.24321/0019.5138.202557>

## I N F O

### Corresponding Author:

Vettrivel Arul, Vinayaka Mission's Homoeopathic Medical College & Hospital, Vinayaka Mission's Research Foundation DU, Salem, Tamil Nadu, India

### E-mail Id:

Veldoc4565@gmail.com

### Orcid Id:

<https://orcid.org/0000-0002-2319-726X>

### How to cite this article:

Malaiyappan P, Prasad S, Arul V, Babudevaraj K, Selvaraj J C. Innovative Insights and Multidimensional Strategies for Addressing Sexually Transmitted Diseases: A Review. J Commun Dis. 2025;57(2):212-227.

Date of Submission: 2025-04-13

Date of Acceptance: 2025-06-10

## A B S T R A C T

Sexually transmitted diseases (STDs) remain a major global health concern, affecting millions of people and causing not only physical symptoms but also emotional and economic hardship. While significant progress has been made in diagnosis, treatment, and prevention, STDs continue to spread due to challenges like antimicrobial resistance, overlooked non-sexual transmission routes, and gaps in our understanding of their broader context. This narrative review explores current research with a fresh, interdisciplinary lens bringing together insights from microbiology, new diagnostic technologies, and cultural perspectives. It highlights critical issues, including rising resistance in lesser-known pathogens, the role of the genital microbiome in infection risk and recovery, and how environmental and societal factors shape disease patterns. The review also examines innovative solutions like point-of-care testing, targeted prevention strategies, and emerging ideas such as microbiome-based therapies, climate-aware health policies, and personalised treatments guided by genomics. By integrating these diverse approaches and embracing global collaboration, we can move toward more effective, inclusive, and forward-thinking strategies for tackling STDs and promoting better sexual health for all.

**Keywords:** Sexually Transmitted Diseases, Genital Microbiota, Non-Sexual Transmission Routes, Overlapping Symptoms

## Introduction

Sexually transmitted diseases (STDs) remain a significant global public health challenge with extensive social and economic implications. These infections have persisted from ancient times to the modern era, transcending geographical and cultural boundaries. Globally, millions of new STD cases are reported annually, with HIV/AIDS continuing as a major concern, affecting over 38 million individuals. Bacterial infections such as chlamydia, gonorrhoea, and syphilis also account for substantial morbidity.<sup>1</sup> The high burden of STDs makes their control a public health priority, particularly among high-risk populations. STDs heighten the risk of HIV transmission and contribute to a range of negative reproductive health outcomes. In response, the World Health Organization Organisation (WHO) has recommended microbiological diagnosis using quality-assured molecular assays to improve case management. The Global Health Sector Strategy on STDs, launched in 2016, aims to eliminate them as a public health threat by 2030.<sup>2</sup> The spread of sexually transmitted infections (STIs) remains an ongoing public health challenge. Awareness of risk factors continues to be critical for the development and implementation of effective preventive interventions.<sup>3</sup> In 2020 alone, an estimated 374 million individuals acquired one of the four curable STDs: chlamydia, gonorrhoea, trichomoniasis, or syphilis. Left untreated, these infections can lead to complications such as pelvic inflammatory disease, infertility, ectopic pregnancy, and neurological sequelae. STDs during pregnancy increase risks of miscarriage, stillbirth, prematurity, and neonatal disability.<sup>4</sup> Beyond physical health, STDs significantly impact mental, social, and economic well-being. However, global progress in STD control remains inadequate. WHO's recent progress report revealed stagnation in efforts, especially in resource-limited settings. Ongoing challenges include limited diagnostic capacity, antimicrobial resistance, and emerging sexually transmissible infections like monkeypox and Ebola.<sup>5</sup> STDs are caused by diverse microorganisms and are primarily transmitted through unprotected sexual contact and exchange of bodily fluids. Despite advances in diagnostics and treatment, prevalence remains high.<sup>6</sup> Routine sexual history-taking, multisite screening, and sensitive diagnostic tools such as nucleic acid amplification tests are critical for early detection. Syphilis diagnosis remains complex and demands clinical vigilance. Preventive measures, including vaccines and post-exposure prophylaxis, offer hope for reducing the STD burden, especially in people with HIV.<sup>7</sup> Even with significant progress in diagnostics, treatments, and prevention, sexually transmitted diseases (STDs) remain a pressing global health concern. Their continued prevalence now complicated by growing antimicrobial resistance and often-overlooked transmission routes highlights the need for more comprehensive and integrated approaches. To

effectively tackle STDs, it's important to look beyond just the clinical aspects. Combining insights from microbiology, advances in diagnostic technologies, and an understanding of social and cultural contexts can help reshape how we approach prevention and care. This review aims to explore the complex nature of STDs, identify gaps that still need attention, and suggest actionable steps to support global sexual health efforts.

## Microbial Perspectives

### Emerging and Re-emerging Pathogens

Sexually transmitted infections (STIs) remain a major global public health concern, with the emergence and re-emergence of certain pathogens further complicating efforts in prevention and treatment. *Mycoplasma genitalium* is an emerging pathogen increasingly linked to nongonococcal urethritis (NGU) in men. Its growing prevalence compared to other STIs is particularly concerning due to challenges in diagnosis and treatment. Laboratory cultivation of *M. genitalium* is difficult, making nucleic acid amplification tests (NAAT) the only dependable diagnostic tool. The rise in antimicrobial resistance to common antibiotics like azithromycin and moxifloxacin highlights the urgent need for standardized standardised treatments and broader diagnostic access. Furthermore, evolving sexual behaviors, such as increased oral and anal sex, suggest that under diagnosis underdiagnosis may be more widespread than previously assumed, especially in settings with limited testing capacity.<sup>8</sup> In parallel, syphilis caused by *Treponema pallidum* has re-emerged globally, with a significant increase in syphilis diagnoses and in the prevalence of the A2058G mutation linked to macrolide resistance during the 2018–2021 period compared to 2006. The higher proportions of MSM within the study population were associated with elevated syphilis rates, identifying this group as particularly vulnerable. The widespread occurrence of A2058G and A2059G mutations worldwide highlights the need for enhanced surveillance, resistance monitoring, and customized customised intervention strategies.<sup>9</sup> The growing impact of *M. genitalium* and the resurgence of syphilis reflect the rapidly evolving STI landscape, necessitating integrated public health responses that prioritize prioritise timely diagnosis, antimicrobial stewardship, and focused outreach to high-risk populations

### Antimicrobial Resistance in Lesser-Known STIs

Antimicrobial resistance (AMR) among lesser-known sexually transmitted infections (STIs) is rapidly emerging as a critical global public health threat, particularly in relation to *Mycoplasma genitalium*, a pathogen increasingly exhibiting resistance to standard antimicrobial therapies. Infections among men who have sex with men (MSM) have shown a concerning pattern, with strains of *M. genitalium*

frequently harboring harbouring macrolide resistance-associated mutations (MRM) and quinolone resistance-associated mutations (QRM), including cases with dual-class resistance, thereby complicating treatment outcomes.<sup>10</sup> These findings emphasize the persistent need for routine screening and resistance profiling within high-risk populations to ensure appropriate and effective clinical management. On a broader scale, the global prevalence of resistance-associated mutations in urogenital mycoplasmas and urea plasmas reinforces the severity of the AMR challenge. Mutations conferring resistance to macrolides, tetracyclines, and fluoroquinolones have been consistently identified in *M. genitalium*, further limiting treatment options and raising the risk of persistent or recurrent infections.<sup>11</sup> A noticeable rise in multidrug-resistant (MDR) strains has been documented in recent years, pointing to the urgency for enhanced international surveillance and the development of novel antimicrobials or combination therapies. A focused study from Belgium on MSM using pre-exposure prophylaxis (PrEP) revealed an exceptionally high prevalence of *M. genitalium* infections with resistance-associated mutations. Among individuals with recurrent STIs, 95.2% of *M. genitalium* strains exhibited resistance to macrolides, while 35.7% showed resistance to fluoroquinolones, indicating the critical role of this subgroup in amplifying the spread of resistant strains.<sup>12</sup> Additionally, genetic mutations are key drivers of resistance in pathogens like *Neisseria gonorrhoeae* and *M. genitalium*, while resistance in *Chlamydia trachomatis* and *Treponema pallidum* remains relatively limited but still a latent concern due to widespread antimicrobial usage. These findings underscore the importance of robust prevention strategies, timely diagnostics, and treatment diversification to combat the growing threat of resistance across both common and lesser-recognized recognised STIs.<sup>13</sup> In essence, as AMR continues to outpace therapeutic advancements, a proactive and integrated approach that blends surveillance, clinical adaptation, and public health innovation is essential to preserving the efficacy of current and future STI management frameworks.

### **Influence of Genital Microbiota on Susceptibility and Outcomes**

The composition of genital microbiota plays a pivotal role in modulating susceptibility to sexually transmitted infections (STIs) and shaping their clinical trajectories. In women, a vaginal microbiota dominated by *Lactobacillus* species particularly *Lactobacillus crispatus* is widely recognized as protective and indicative of optimal reproductive health. When these beneficial lactobacilli are depleted, the vaginal environment becomes more conducive to colonization colonisation by anaerobic pathogens, often clinically manifesting as bacterial vaginosis (BV), a condition strongly associated with increased risk for a

range of STIs.<sup>14</sup> This dysbiotic state has been correlated with heightened susceptibility to pathogens such as *Neisseria gonorrhoeae*, *Chlamydia trachomatis*, *Trichomonas vaginalis*, Human papillomavirus (HPV), Herpes simplex virus (HSV), *Mycoplasma genitalium*, and most notably, with both acquisition and transmission of HIV.<sup>15</sup> The mechanisms underpinning this increased vulnerability include compromise of the epithelial barrier, elevation of inflammatory cytokines, and production of metabolites that may enhance pathogen infectivity.<sup>14</sup> Studies have demonstrated that a diverse, non-*Lactobacillus*-dominated vaginal microbiota is independently associated with higher rates of incident infections, such as *Trichomonas vaginalis* and HPV, irrespective of sexual behavior, thereby reinforcing the direct role of microbiota composition in infection risk.<sup>16</sup> Interestingly, the genital microbiota's influence extends to men as well. Uncircumcised men typically exhibit a higher penile bacterial load, with an increased presence of anaerobic species, including those associated with BV. Male circumcision has been shown to significantly alter the penile microbiome, reducing microbial diversity and bacterial density, which has been associated with a decreased risk of acquiring HIV, HSV-2, and HPV. Moreover, circumcision has shown indirect protective effects for female partners by lowering their risk of bacterial vaginosis (BV), highlighting the intricate interplay between male and female genital microbiota in the transmission dynamics of STIs.<sup>15,17</sup> In women, BV-induced dysbiosis has been implicated in facilitating HIV acquisition, likely due to the inflammatory microenvironment and mucosal barrier disruption. Specific bacterial species such as *Prevotella* and *Sneathia amnii* have been directly associated with elevated HIV risk, highlighting the importance of maintaining a eubiotic, *Lactobacillus*-rich vaginal microbiome.<sup>18</sup> Advancements in molecular diagnostics, particularly through 16S rDNA sequencing technologies, have enabled more nuanced characterization characterisation of the vaginal microbiota and its relationship with STIs. These methods have revealed distinct bacterial community structures that influence susceptibility to infections such as HIV, suggesting that modulation of the vaginal microbiota could serve as a promising preventive strategy.<sup>19</sup> Furthermore, the genital microbiome may also impact the efficacy of biomedical prevention tools. For example, studies have shown that non-optimal microbiota particularly those with high relative abundance of *Gardnerella vaginalis* can reduce the effectiveness of vaginal tenofovir-based microbicides, indicating that microbiota composition should be considered when developing and deploying STI prevention modalities.<sup>20</sup> It is crucial to account for the condition of vaginal microbiota when designing and executing strategies for STI prevention. The genital microbiota plays a significant role in determining susceptibility to STIs and their clinical progression. A

balanced, lactobacilli-dominated microbiota tends to offer protection against various STIs, whereas dysbiosis can heighten susceptibility and undermine treatment effectiveness. Gaining a deeper understanding of these interactions is essential for crafting effective approaches to the prevention and management of STIs.

## Transmission Dynamics

### Beyond Sexual Contact: Rare Non-Sexual Transmission Routes

While sexually transmitted diseases (STDs) are primarily transmitted through sexual contact, a growing body of evidence highlights the possibility of non-sexual transmission routes, particularly via fomites objects or materials likely to carry infectious agents, such as towels, bedding, clothing, or improperly sanitized medical instruments. Recognizing these alternative pathways is essential for a holistic approach to STD prevention and control. Notably, *Chlamydia trachomatis*, the causative agent of chlamydial infections, has been shown to survive on nonporous surfaces under specific environmental conditions. Research has indicated that under humid settings, *C. trachomatis* can remain viable on plastic surfaces for extended durations, suggesting that indirect transmission, especially to non-genital sites like the conjunctiva, is biologically plausible and may lead to conditions such as chlamydial conjunctivitis.<sup>20</sup> Beyond environmental surfaces, healthcare-associated settings have demonstrated the potential for STD-related pathogens and other infectious agents to spread via contaminated medical equipment. Inadequate cleaning, disinfection, or sterilization of instruments has been implicated in outbreaks involving multidrug-resistant organisms, further emphasizing the need for strict adherence to infection control protocols. The improper handling of patient-care items in clinical environments can inadvertently facilitate pathogen transmission, underscoring the critical importance of effective sterilization procedures.<sup>21</sup> In addition to inanimate objects, personal items worn or used by healthcare workers themselves can serve as unintentional vectors for pathogen spread. The presence of bacteria such as *Staphylococcus aureus* and gram-negative rods on commonly used articles, including white coats, neckties, stethoscopes, and mobile phones. While a direct causative link to patient infections has yet to be conclusively established, the high levels of microbial contamination on these personal items highlight a potentially overlooked risk factor within healthcare environments. These findings reinforce the importance of routine disinfection and the implementation of evidence-based hygiene measures among healthcare personnel to minimize potential exposure risks.<sup>22</sup> Although sexual activity remains the principal route of STD

transmission, awareness of non-sexual transmission through fomites and contaminated tools expands our understanding of infection dynamics. Mitigating these less conventional yet plausible pathways through stringent hygiene practices, equipment sterilization, and environmental decontamination is vital to strengthening STD prevention efforts and safeguarding public health.

### Insights into Mother-to-Child Spread Transmission

Mother-to-child transmission (MTCT) of sexually transmitted infections (STIs) represents a persistent global health challenge, with multiple pathogens contributing to adverse maternal and neonatal outcomes. Syphilis, caused by *Treponema pallidum*, is a prime example, as untreated maternal infection is associated with fetal foetal loss, premature birth, congenital syphilis, and neonatal death; however, timely detection and treatment before the third trimester can normalize the risk to background levels.<sup>23</sup> The complexity of MTCT increases in the presence of co-infections, particularly with HIV. An Indian study highlighted that maternal syphilis co-infection nearly doubled the risk of HIV transmission to the infant by six months of age, reinforcing the critical need for integrated STI screening during pregnancy.<sup>24</sup> Other common STIs such as *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and *Trichomonas vaginalis* also pose MTCT risks. A South African study reported frequent detection of these pathogens in the nasopharynx of newborns born to HIV-infected mothers, raising questions about the long-term implications of early-life colonization.<sup>25</sup> Nonetheless, population-level data from a nationwide study revealed a lower incidence of *C. trachomatis* infections in infants, with a rate of just 0.22 per 1000 live births and a vertical transmission risk under 2%, indicating that MTCT rates can vary widely depending on healthcare access and screening protocols.<sup>26</sup> Hepatitis B virus (HBV) MTCT remains a major concern, especially in high-burden regions where antenatal screening and prophylactic interventions such as antiviral therapy and timely birth-dose vaccination are not universally accessible.<sup>27</sup> In response, the World Health Organization's Triple Elimination Initiative promotes an integrated strategy targeting the elimination of MTCT of HIV, syphilis, and HBV through antenatal testing, prompt treatment, safe childbirth practices, and appropriate infant follow-up.<sup>28</sup> The complexities surrounding MTCT of sexually transmitted infections (STIs) are shaped by a multitude of factors, including maternal co-infections, regional disparities in healthcare infrastructure, and unequal access to preventive interventions. Addressing these challenges requires a multifaceted approach; comprehensive antenatal screening, timely diagnosis and treatment, and the implementation of integrated, evidence-based healthcare strategies are essential to effectively reduce MTCT risks and enhance neonatal health outcomes

## Epidemiology Across Unconventional Demographics

Recent studies have revealed notable shifts in the epidemiology of sexually transmitted diseases (STDs), particularly among demographic groups traditionally perceived as lower risk, emphasizing the need for inclusive and equitable sexual health strategies. A significant rise in STD cases has been observed in the elderly population, with conditions such as candidial balanoposthitis, herpes genitalis, and genital warts emerging as the most common diagnoses in this age group.<sup>29</sup> Transgender individuals are disproportionately affected by STDs, with laboratory confirmed data indicating high prevalence rates of HIV and syphilis among both transgender women and men. These elevated infection rates are closely associated with barriers such as limited access to competent healthcare, pervasive societal stigma, and engagement in high-risk sexual behaviors.<sup>30</sup> Individuals with disabilities represent a population disproportionately impacted by sexually transmitted diseases (STDs). Among them, women of reproductive age with cognitive or multiple disabilities experience more than twice the prevalence of STDs compared to women without disabilities.<sup>31</sup> This heightened vulnerability is attributed to several interrelated factors, including limited access to comprehensive sexual health education and an increased risk of sexual exploitation and abuse.<sup>32</sup> Rural populations also face distinct obstacles in STD prevention and care; a narrative review highlighted that limited access to healthcare services, inadequate screening infrastructure, and the influence of conservative social norms contribute to heightened STD risks in these communities.<sup>33</sup> These findings stress the urgency of broadening sexual health services and education to encompass all population groups, regardless of age, gender identity, disability status, or geographical location. Addressing the specific vulnerabilities and healthcare needs of these underrepresented communities is essential for curbing the spread of STDs and advancing comprehensive public health outcomes.

### Advances in Diagnostics

#### Innovations in Point-of-Care Testing for Remote Settings

Sexually transmitted infections (STIs) continue to represent a major public health concern, particularly in remote and resource limited regions where access to advanced laboratory infrastructure is often inadequate. In such settings, the introduction of point-of-care (POC) diagnostic tools has significantly improved STI detection and management by enabling rapid, accurate, and user-friendly testing that facilitates timely diagnosis and treatment, thereby reducing disease transmission.<sup>34</sup> A key advancement in this domain has been the development of nucleic acid amplification

tests (NAATs), which are capable of detecting even minute quantities of pathogen DNA or RNA. NAATs have proven highly sensitive and reliable, especially when compared to conventional antigen-based assays, and are effective in identifying infections like *Chlamydia trachomatis* and genital herpes. These tests also accommodate non-invasive sampling, making them suitable for broader community-based screening initiatives.<sup>35</sup> In rural contexts, mobile health clinics have played an essential role in extending POC diagnostic capabilities to underserved populations. For example, in Alabama's Blackbelt Black Belt region, the deployment of the Binx IO® system for testing chlamydia and gonorrhea demonstrated that mobile clinics can successfully bridge diagnostic gaps in STI care. Both healthcare providers and patients reported high satisfaction regarding the accessibility and workflow efficiency of the testing process.<sup>36</sup> Implementation studies have further emphasized the need to address systemic challenges in scaling up POC diagnostics, highlighting requirements for skilled personnel, training programs, infrastructural support, and cost-effective resource allocation. These elements are critical to ensuring the sustainability and success of POC interventions in low-resource environments.<sup>4</sup> The evolution of POC technology has also led to the creation of assays that fulfill the World Health Organization's ASSURED criteria tests that are Affordable, Sensitive, Specific, User-friendly, Rapid, Equipment-free, and Deliverable to end users. Such innovations have been instrumental in supporting large scale STI screening, particularly where access to electricity or refrigeration is limited, making them especially valuable in remote and underserved communities.<sup>37</sup> Despite these promising developments, barriers to widespread POC adoption persist, including logistical, economic, and infrastructural constraints.<sup>34</sup> Nonetheless, the continual advancement and strategic deployment of POC diagnostics offer immense potential to transform STI care in marginalized settings, and ongoing efforts to refine and integrate these tools are essential to improving global sexual and reproductive health outcomes.

#### Molecular Diagnostics: Detecting Resistance Markers

The growing threat of antimicrobial resistance (AMR) among sexually transmitted pathogens has catalyzed the advancement of molecular diagnostics capable of detecting rare genetic markers linked to resistance. These innovations are essential for the early identification and precise management of resistant or uncommon sexually transmitted infections (STIs). In the case of *Trichomonas vaginalis*, a significant breakthrough was the identification of 72 single nucleotide polymorphisms (SNPs) associated with metronidazole resistance. These mutations were observed in both uncharacterized genes

and genes previously implicated in drug resistance, such as pyruvate: ferredoxin oxidoreductase, highlighting the potential of SNP profiling as a diagnostic approach for resistant *T. vaginalis* infections.<sup>38</sup> For *Neisseria gonorrhoeae*, considerable progress has been made in developing molecular assays, including a real-time PCR assay that effectively identifies the penA-60 allele associated with ceftriaxone resistance. The validation of this assay demonstrated its clinical relevance in enabling rapid and targeted detection, thereby supporting tailored treatment decisions.<sup>39</sup> The adoption of next generation sequencing (NGS) has further enhanced the capacity to predict antimicrobial resistance in *N. gonorrhoeae*. By providing comprehensive analysis of resistance conferring genetic determinants, NGS outperforms traditional nucleic acid amplification tests (NAATs), especially in predicting resistance to cephalosporins and azithromycin.<sup>40</sup> Moreover, technological advancements have led to the development of rapid molecular assays capable of detecting multiple STI pathogens and their corresponding resistance mutations within approximately 35 minutes. These assays can simultaneously identify *Neisseria gonorrhoeae*, *Chlamydia trachomatis*, *Trichomonas vaginalis*, and *Mycoplasma genitalium*, as well as macrolide (23S rRNA gene A2058/A2059) and fluoroquinolone (ParC gene S831) resistance associated mutations, offering a time-efficient and comprehensive diagnostic solution.<sup>41</sup> Commercial molecular tests have also been evaluated for detecting fluoroquinolone resistance in *M. genitalium*, showcasing their value in guiding appropriate therapeutic strategies and mitigating treatment failures.<sup>42</sup> In addition to diagnosing typical and symptomatic cases, molecular diagnostic tools have been instrumental in identifying atypical, asymptomatic, and co-infections. Their non-diagnostic applications span a wide range of public health activities, including screening high-risk populations, monitoring treatment outcomes, outbreak investigation, validation of syndromic management protocols, and surveillance of resistance patterns, particularly in *N. gonorrhoeae*. These tools also support laboratory quality assurance and research. Laboratory diagnosis of STIs traditionally includes direct microscopy, culture techniques, antigen and antibody detection, metabolic assays such as the Whiff test, and more recently, molecular diagnostics. The integration of molecular methodologies has markedly improved the detection and characterization of resistant and hard-to-cultivate organisms, offering superior sensitivity and specificity.<sup>43</sup> The evolution of molecular diagnostics has transformed STI detection and resistance profiling, serving as a cornerstone in the effective management and control of resistant and atypical infections and contributing meaningfully to public health advancement.

## Diagnostic Challenges: Overlapping Symptoms Delaying Care

Sexually transmitted infections (STIs) frequently present with nonspecific and overlapping symptoms, making accurate clinical diagnosis and prompt treatment particularly challenging. This issue is compounded by the high proportion of asymptomatic infections, which often go unnoticed and untreated, thereby increasing the risk of transmission and complications. For example, a study found that women who tested positive for one or more STIs often did not receive appropriate treatment within a week of clinical consultation, largely due to the difficulty in differentiating between urinary tract infections (UTIs) and STIs based solely on symptoms, leading to misdiagnosis and delayed care.<sup>44</sup> Similarly, several cases of colorectal STIs were initially misdiagnosed as inflammatory bowel diseases (IBD). These cases primarily involved men who have sex with men, many of whom were HIV-positive, and the correct diagnosis was delayed by up to three years due to overlapping clinical and endoscopic features with IBD.<sup>45</sup> Additionally, research among female sex workers highlighted the limitations of symptom-based STI diagnosis, particularly in settings where laboratory-based testing is unaffordable or inaccessible. While laboratory tests remain the diagnostic gold standard, they are not always feasible in low-resource contexts. As a result, reliance on symptomatic diagnosis can result in both under- and over-treatment, especially given the high incidence of asymptomatic infections.<sup>46</sup> To address diagnostic limitations in resource-constrained environments, the World Health Organization Organisation has promoted a syndromic management approach, which relies on treating patients based on recognizable symptom clusters. Although this strategy has contributed to a reduction in some STI rates, it remains insufficient due to its limited accuracy and inability to detect asymptomatic cases effectively.<sup>47</sup> The frequent overlap of STI symptoms with other conditions, coupled with the silent nature of many infections, necessitates the adoption of enhanced diagnostic strategies. Expanding access to affordable testing, promoting routine screening, and improving clinical awareness are critical steps toward strengthening STI management and improving sexual and reproductive health outcomes globally.

## Prevention Strategies

### Behavioral Behavioural and Cultural Insights in Prevention

Cultural practices and societal norms play a critical role in shaping the success of sexually transmitted disease (STD) prevention strategies across different regions. In many parts of the world, including both Western and Asian countries, a diagnosis of human papillomavirus (HPV) often carries a

moral stigma, which contributes to significant psychological and social burdens for affected individuals.<sup>48</sup> Embarrassment and stigma surrounding HPV vaccination have persisted since the introduction of the first HPV vaccine, limiting its widespread acceptance. Compared to Western societies, many Asian cultures exhibit more conservative attitudes toward sexuality. Sex-related topics are often considered taboo, with discussions about sexual health regarded as inappropriate or even obscene.<sup>49</sup> This deeply rooted conservatism prevents open dialogue within families and communities, especially between parents and children, thus reducing awareness and access to sexual health education. Consequently, individuals may hesitate to seek preventive measures like the HPV vaccine out of fear of being labeled as promiscuous.<sup>48</sup> Traditional beliefs and cultural customs also influence health-seeking behaviors. In many cases, individuals particularly women opt for traditional remedies over medical interventions due to fear, embarrassment, or social stigma. A study highlighted that such choices were often driven by cultural norms, fear of being identified as having a sexually transmitted infection, and systemic barriers within healthcare systems.<sup>50</sup> For instance, in Malaysia, despite the availability of free HPV vaccinations through the national immunization program, some parents still refused to vaccinate their children due to cultural beliefs and preference for traditional medicine.<sup>51</sup> The widespread reliance on traditional health practices in many Asian countries, rooted in historical and cultural values, can inadvertently lead to the neglect of scientifically supported preventive measures like screening and vaccination. These insights highlight the importance of culturally sensitive awareness campaigns that not only dispel myths surrounding traditional remedies but also promote evidence-based medical practices to prevent STDs.<sup>48</sup> Gender dynamics further influence the efficacy of STD prevention strategies. In many Asian societies, male partners often play a decisive role in family planning, including contraceptive use and the number of children desired. Studies have shown that a woman's ability to use contraception may be contingent on her husband's approval, underscoring the need for gender-equitable health decision-making.<sup>52</sup> Empowering women through education and fostering joint decision-making in relationships are vital to enhancing sexual health outcomes.<sup>48</sup> Moreover, integrating traditional healers into public health campaigns such as those related to HIV/AIDS has proven beneficial in aligning traditional practices with modern medical approaches. These partnerships help build trust within communities and support a more comprehensive, culturally resonant prevention strategy.<sup>53</sup> Understanding cultural context is therefore essential when developing effective behavioral interventions for STD prevention. For example, research has emphasized the

importance of identifying culturally specific reasons for inconsistent condom use, which vary significantly across regions and communities. Tailoring educational programs to address these cultural barriers can enhance the efficacy of interventions.<sup>54</sup> Community-based education and collaboration with local leaders are key strategies for overcoming societal taboos and encouraging open conversations about sexual health. Ultimately, incorporating cultural and behavioral insights into STD prevention efforts is essential. By recognizing and addressing the diverse societal norms and traditions that influence health behaviors, prevention strategies can be effectively customized to support sexual health and reduce STD transmission on a broader scale.

### **Tech-Based Approaches: Digital Tools for Sexual Health Awareness**

The integration of digital technologies particularly mobile applications and online platforms has revolutionized the landscape of sexual health education by offering accessible, engaging, and user-driven methods for promoting awareness and preventing sexually transmitted diseases (STDs). A systematic literature review encompassing 9,881 records revealed that websites and mobile phones are the primary digital channels used in sexual health interventions to deliver both cognitive and behavioral outcomes. These include improvements in knowledge and attitudes related to sexual and reproductive health, as well as behavioral changes such as increased contraceptive use and delayed sexual initiation. Among the digital formats evaluated, interactive websites, text messaging, phone calls, and online educational programs were identified as the most effective mechanisms for health promotion, demonstrating significant influence on users' knowledge and behavior.<sup>55</sup> Mobile applications, in particular, have emerged as innovative tools that provide personalized and interactive experiences to improve sexual and reproductive health. For example, the "Crush" mobile application was specifically developed to promote the use of sexual and reproductive health services and contraceptives among adolescent girls. Users of the Crush app demonstrated higher confidence in accessing these services and greater belief in the importance of consistent contraceptive use when compared to a control group. These findings underscore the potential of mobile apps to enhance knowledge, shape positive attitudes, and build self-efficacy regarding sexual and reproductive health practices.<sup>56</sup> In addition to general education, digital tools are increasingly being tailored to meet the needs of specific populations. The "SavvyHER" app, designed for Black women in the southern United States, focused on sexual and reproductive health

and HIV prevention. A pre-test evaluation of the app found high levels of user acceptability, with participants actively engaging in live group discussions, utilizing educational content, and accessing mental health and physical activity monitoring features. These results suggest that culturally sensitive digital interventions can effectively address the specific health needs of targeted demographics by providing relevant and holistic support.<sup>57</sup> Beyond educational content, digital platforms have also been leveraged to enhance STD screening and counseling. One such initiative combined telehealth services with motivational interviewing (MI) to promote STD screening among sexually active men who have sex with men (MSM) living with HIV. This protocol incorporated home specimen self-collection kits and live video consultations using MI techniques to encourage screening for bacterial STDs. The integration of digital communication tools with behavioral counseling illustrates a promising strategy for increasing engagement and compliance in populations at high risk for STDs.<sup>58</sup> Leveraging digital tools such as mobile applications, interactive websites, and telehealth platforms provides a forward-looking approach to enhancing sexual health education and STD prevention. These technologies facilitate the delivery of accurate, personalized, and culturally relevant information, particularly for youth and marginalized populations. However, for these interventions to reach their full potential, continued emphasis must be placed on ensuring the reliability of health information, promoting digital literacy, and addressing technological barriers to access. By addressing these factors, digital sexual health interventions can serve as powerful tools in improving public health outcomes on a broader scale.

### **Community-Driven Solutions: Grassroots Initiatives**

Community-based interventions have emerged as a powerful and effective strategy in addressing the burden of sexually transmitted diseases (STDs), particularly among marginalized and underserved populations. A notable example includes a comprehensive HIV prevention program targeting female sex workers (FSWs), which successfully reached a significant proportion of the mapped FSW population. As part of the intervention, women received condoms as needed and were able to access essential health services for sexually transmitted infections. Between 2008 and 2011, this initiative led to a notable increase in condom use and a rise in the utilization of HIV counseling and testing services, showcasing the efficacy of rural outreach models grounded in community participation and accessibility.<sup>59</sup> Another prominent initiative is the Community Approaches to Reducing STDs (CARS), developed by the U.S. Centers for Disease Control and Prevention. This program emphasizes

programme emphasises community engagement to advance STD prevention, screening, and treatment efforts, particularly in communities disproportionately affected by STD-related health disparities. CARS focuses on addressing locally prioritized social determinants of health and targets specific vulnerable groups such as youth, persons of color, and sexual and gender minorities. By involving the community directly in the identification of needs and in strategy development, this initiative provides a replicable model for reducing STD disparities through context-specific approaches.<sup>60</sup> Stigma remains a substantial barrier to effective sexual health promotion, especially in rural areas. In response, engaging local community members particularly men as lay health advisors have proven instrumental in developing and executing STI/HIV prevention strategies. This grassroots method not only fosters trust but also addresses the cultural and social dynamics that often impede open discussions about sexual health. It further reinforces the value of community ownership in dismantling stigma and improving overall health outcomes.<sup>61</sup> Despite their potential, community-wide and multilevel STI interventions often face challenges such as limited coordination among stakeholders and competition for limited funding resources. Nonetheless, collaborative efforts involving schools, after-school programs, community-based organizations, and healthcare facilities have shown success in implementing comprehensive interventions aligned with the Institute of Medicine's spectrum of preventive strategies. These efforts highlight the importance of synergy among multiple sectors in addressing the complex determinants of STDs.<sup>62</sup> Addressing health disparities necessitates more than isolated clinical efforts; it requires a comprehensive response to immediate community needs and a focused engagement with the social determinants that perpetuate inequities. While community engagement is frequently advocated as a core public health principle, its application in STD prevention, screening, and treatment has been limited in real-world practice. Guidance on critical components of effective community engagement can serve as a valuable resource for public health practitioners, researchers, and their partners, ensuring that strategies are both inclusive and responsive to the lived experiences of affected populations.<sup>60</sup> Community-based interventions serve as an essential pillar in the fight against STDs. By actively involving local populations, addressing social determinants, and fostering culturally competent strategies, these interventions offer a sustainable path forward for reducing STD disparities and promoting sexual health equity across diverse communities. By getting local people involved, tackling social issues, and creating strategies that respect different cultures, these interventions provide a lasting way to lower STD differences and support sexual health fairness in various communities.



## Innovative Treatment Approaches

### Addressing Multidrug Resistance: Therapies and Biomedical Prevention

The escalating challenge of antimicrobial resistance (AMR) in sexually transmitted infections (STIs), particularly *Neisseria gonorrhoeae*, has become a pressing global public health concern. *Gonorrhea* has exhibited a remarkable ability to develop resistance to nearly all classes of antibiotics previously used for treatment, including sulfonamides, sulphonamides, penicillins, penicillin's, tetracyclines, macrolides, and fluoroquinolones, leaving extended-spectrum cephalosporins especially ceftriaxone as the last reliable monotherapy option in many settings.<sup>63</sup> Alarming reports of ceftriaxone-resistant gonococcal strains have intensified the urgency for novel treatment modalities.<sup>64</sup> To address the growing threat of antimicrobial resistance in *Neisseria gonorrhoeae*, novel antimicrobials have been developed that specifically target bacterial DNA biosynthesis by inhibiting type II topoisomerases.<sup>65</sup> Among these, zoliflodacin a first-in-class spiropyrimidinetrione has demonstrated significant efficacy by uniquely inhibiting DNA gyrase and topoisomerase IV, mechanisms that differ from those of currently used antibiotics. This distinct mode of action offers a promising avenue to circumvent existing resistance mechanisms.<sup>63</sup> Similarly, gepotidacin, a triazaacenaphthylene antibiotic, exerts its effect by binding to novel sites on DNA gyrase and topoisomerase IV, distinct from fluoroquinolones. This innovative binding profile reduces the potential for cross-resistance, positioning gepotidacin as a strong candidate in the therapeutic arsenal against multidrug-resistant *N. gonorrhoeae*.<sup>65</sup> In addition to these agents, JSF-2414 a tricyclic pyrimidoindole compound has emerged as another promising antimicrobial. It is engineered to simultaneously inhibit the ATP-binding domains of both DNA gyrase subunit GyrB and topoisomerase IV subunit ParE, thereby enhancing its potency against drug-resistant gonococcal strains. The phosphate prodrug form of JSF-2414, known as JSF-2659, has shown remarkable efficacy in preclinical models, achieving near-complete microbial clearance in animal models of vaginal gonococcal infection.<sup>63</sup> In parallel with therapeutic advancements, new biomedical prevention strategies are being investigated to further control bacterial STIs. These include the use of antibacterial mouthwashes and doxycycline as post-exposure chemoprophylaxis interventions that may help reduce transmission rates, particularly in high-risk populations.<sup>66</sup> Addressing the threat of antimicrobial resistance in STIs requires a coordinated, multidisciplinary effort. Continued investment in antimicrobial research, combined with robust surveillance systems, targeted public health interventions, and global collaboration, is essential to ensure the availability of

effective treatment options. These efforts are critical not only for controlling gonorrhoea but also for preserving the broader effectiveness of antibiotics in managing infectious diseases.

### Tackling Stigma and Social Barriers in Treatment Access

Stigma surrounding sexually transmitted infections (STIs) remains a significant barrier to effective public health responses, as it discourages individuals from seeking timely testing and treatment. This stigma often manifests within healthcare settings through institutional practices and policies that inadvertently segregate or discriminate against individuals based on perceived sexual behaviors. Many individuals report avoiding STI-related services due to previous experiences of discrimination, indifference, or overt hostility from healthcare providers. Globally, structural barriers such as limited access to comprehensive reproductive health services for marginalized populations like new immigrants, criminalization of behaviors linked to STI transmission (e.g., commercial sex work and same-sex relationships), and policies that restrict access to scientifically accurate information (e.g., abstinence-only education) perpetuate systemic stigma within sexual and reproductive health frameworks.<sup>67</sup> The intersectionality of stigma is especially profound among sexually diverse Muslim men, who often navigate complex identities that expose them to layered discrimination based on both sexual orientation and religious background. For many in this population, limited awareness, fear of disclosure, and prior negative healthcare experiences deter engagement with sexual health services, underscoring the importance of culturally sensitive, inclusive interventions tailored to their specific needs.<sup>68</sup> At the institutional level, stigma is reinforced by healthcare providers' personal biases, fears, and inadequate awareness, all of which contribute to unequal or dismissive treatment of patients seeking care. These dynamics foster an environment where individuals may delay or avoid healthcare altogether, leading to worsened health outcomes and continued transmission risks.<sup>69</sup> To address these challenges, a multifaceted approach is required one that integrates person-centered care models, trauma-informed practice, comprehensive sex-positive education, and meaningful community involvement. Such strategies not only reduce stigma but also enhance access to essential STI prevention and treatment services.<sup>70</sup> In Central and Eastern Europe, for instance, HIV-related stigma has been a persistent barrier to testing and care. However, targeted interventions that promote the "undetectable = untransmittable" (U=U) message, provide stigma-reduction training for healthcare professionals, and advocate for policy reform have shown considerable promise in reducing stigma and increasing healthcare

engagement.<sup>71</sup> Dismantling STI-related stigma requires concerted, culturally aware, and systemic interventions. By fostering inclusive healthcare environments and addressing stigma at multiple levels individual, institutional, and societal public health efforts can more effectively reduce transmission, improve outcomes, and promote equity in sexual health care.

## Broader Implications

### Psychological Impact and Resilience Mechanisms

Individuals diagnosed with sexually transmitted infections (STIs) often endure considerable psychological distress, which can manifest as shame, anxiety, depression, and a profound sense of isolation. These emotional consequences extend beyond the physical symptoms of the infection, deeply influencing patients' mental health and overall quality of life. Research has shown that individuals with STIs frequently experience embarrassment, fear of rejection, and concerns about sexual desirability, all of which can lead to diminished self-worth and social withdrawal.<sup>72</sup> Such internalized stigma not only impairs psychological well-being but also contributes to reluctance in seeking medical care or disclosing STI status to sexual partners, thereby exacerbating public health risks. The bidirectional relationship between mental health and STIs is well documented. While individuals with pre-existing mental health conditions are at increased risk of acquiring STIs due to factors like impaired judgment or risky sexual behavior, those diagnosed with STIs are similarly vulnerable to developing mental health issues post-diagnosis.<sup>73</sup> In an effort to mitigate the psychological toll of an STI diagnosis, patients often resort to various coping strategies. Problem-focused coping, which involves actively seeking information and engaging in open communication, has been linked to more favorable psychological outcomes. For instance, studies among women exposed to gender-based violence highlight that proactive coping behaviors such as reaching out for social support and engaging in structured problem-solving can reduce levels of distress.<sup>74</sup> Functional social support, comprising tangible aid, emotional guidance, and positive social interaction, plays a critical role in mental health outcomes among women with sexually transmitted infections (STIs). Limited emotional and tangible support is linked to increased depressive symptoms, with emotional and informational support proving more protective than affection or material help. Encouraging young women with STIs to build reciprocal relationships through social and community engagement can enhance coping and reduce psychological distress.<sup>75</sup> Addressing the psychological dimensions of STI diagnoses is integral to holistic sexual health care. By creating supportive environments, facilitating access to mental health services, and empowering individuals through community-based

engagement, it is possible to significantly reduce the emotional burden associated with STIs and promote long-term well-being.

### Climate Change and Its Influence on STD Epidemiology

Climate change is increasingly recognized as a pressing public health crisis, with far-reaching implications that extend to the spread and management of sexually transmitted diseases (STDs). A growing body of evidence has linked environmental stressors such as rising temperatures, extreme weather events (EWEs), and economic destabilization to changes in STD transmission dynamics and barriers to healthcare access. In India, elevated temperatures have been associated with increased rates of STDs among vulnerable populations, particularly female sex workers (FSWs), who often operate within informal and unstable work environments. These conditions leave them disproportionately affected by climate anomalies, with studies revealing a suggestive correlation between heat exposure and heightened infection rates in this group.<sup>76</sup> The broader health implications of EWEs further threaten sexual health through multiple pathways, including increased exposure to HIV and other STDs, disrupted access to healthcare services, and heightened incidents of sexual and gender-based violence (SGBV). The World Health Organization outlines four core components essential for sexual health: comprehensive sexuality education; prevention and care for HIV and STIs; prevention and care for SGBV; and psychosexual counselling.<sup>77</sup> Adolescent girls and young women (AGYW) in low- and middle-income countries (LMICs) are especially vulnerable in the face of climate-related adversities. These include not only the direct health threats of STIs but also related socio-economic impacts such as poverty, food insecurity, school dropout, early marriage, transactional sex, and sexual violence all of which heighten the risk of poor sexual and reproductive health (SRH) outcomes.<sup>78</sup> Environmental instability caused by droughts, cyclones, floods, and rainfall shocks has also been linked to increased rates of HIV prevalence, gender-based violence, and adverse maternal and neonatal outcomes. Such disruptions strain already fragile healthcare infrastructures, impeding timely diagnosis and treatment while simultaneously increasing risk exposure and unsafe sexual practices.<sup>79</sup> In light of these challenges, climate-resilient sexual health strategies are vital. These should integrate the anticipated impacts of extreme weather events into existing health programs to proactively address emerging SRH needs and strengthen community-level adaptive capacities.<sup>80</sup> These findings underscore the complex interplay between climate change and sexual health, emphasizing the necessity for holistic, context-sensitive responses that can mitigate the growing risks faced by vulnerable populations.

## Interaction of STDs with Broader Health Outcomes

Sexually transmitted infections (STIs) often present without symptoms particularly among women which contributes significantly to underdiagnosis and underreporting. The asymptomatic nature of many STIs delays timely treatment and increases the risk of long-term health complications. When left untreated, STIs can result in chronic pelvic pain, infertility, miscarriage, neonatal mortality, and a heightened susceptibility to HIV infection. Additionally, they are linked to severe outcomes such as genital and oral cancers, as well as neurological and rheumatological complications.<sup>81</sup> STIs, caused by a wide range of pathogens including bacteria, viruses, and protozoa, also play a critical role in male infertility through various pathophysiological mechanisms. These infections not only impact reproductive health directly but can also be horizontally transmitted to sexual partners or vertically passed from mother to child during pregnancy or childbirth. Numerous pathogens such as *Chlamydia trachomatis*, *Ureaplasma* spp., human papillomavirus (HPV), hepatitis B and C viruses, HIV-1, and human cytomegalovirus have been detected in semen samples of both symptomatic and asymptomatic men suffering from testicular, accessory gland, or urethral infections. These infections have been closely associated with impaired semen parameters, including reduced sperm quality, concentration, and motility.<sup>82</sup> These findings emphasize the critical need for early detection and management of STIs, not only to prevent serious health outcomes in individuals but also to mitigate broader reproductive and public health risks through effective control of pathogen transmission.

## Future Direction

Addressing the complex burden of sexually transmitted diseases (STDs) requires interdisciplinary collaboration and innovative policies. A future-oriented approach must integrate medical, technological, and social frameworks to enhance prevention, diagnosis, and treatment. One emerging area of interest is the application of microRNAs (miRNAs) as biomarkers, offering potential for earlier, more precise detection and targeted interventions. To fully leverage this technology, collaboration between molecular scientists, clinicians, and data analysts is essential for developing reliable diagnostics and identifying novel therapeutic targets.<sup>83</sup> Community engagement remains a cornerstone of sustainable STD prevention. Applying the socio-ecological model, community-based STI interventions have involved individual-level consultations and co-creation, peer-led and social network strategies at the interpersonal level, and multisectoral stakeholder partnerships at the community and organizational levels. Policy-level efforts have benefited from digital platforms and community dialogues, reinforcing the value of inclusive, multilevel engagement.

Digital technologies, especially, have broadened outreach and education.<sup>84</sup> Social media platforms like Facebook, Instagram, Twitter, and YouTube have proven effective in disseminating STD prevention messages and engaging youth in sexual health campaigns. When combined with other interventions, Web 2.0 tools can serve as powerful public health instruments for awareness and behavior change.<sup>85</sup> Beyond physical symptoms, STDs carry significant social and economic consequences, including stigma, reproductive complications, and psychological distress. These outcomes strain healthcare systems and affect quality of life. The global response led by governments and international agencies has involved scaling up sexual health education, testing, and treatment services. Future policies must address health disparities and cultural influences on STD transmission. Continued innovation, research, and international commitment are essential to reduce STD burden and promote sexual well-being for all.<sup>1</sup> These multidisciplinary efforts grounded in science, community participation, and digital innovation can significantly strengthen global responses to STDs. By addressing medical, behavioral, and structural determinants in tandem, we move closer to equitable and effective sexual health systems worldwide.

## Conclusion

Addressing sexually transmitted diseases (STDs) requires innovative and interdisciplinary strategies that extend beyond traditional public health approaches. Emerging avenues such as climate-resilient health policies, microbiota-targeted therapies, and digital platforms for personalized health education offer promising potential. Emerging avenues, such as climate-resilient health policies, microbiota-targeted therapies, and digital platforms for personalized health education, offer promising potential. Recognizing the influence of environmental factors, including climate change, on STD epidemiology provides novel insights for surveillance and intervention. Furthermore, integrating socio-cultural understanding with global partnerships can help dismantle persistent barriers to prevention and care. Advances in microbiome research and genomic technologies present exciting opportunities for individualized STD prevention through tailored probiotics, precision vaccines, and synthetic biology-based solutions. These personalized, microbiome-informed approaches remain unexplored but could transform future STD control by addressing individual susceptibilities and enhancing innate defence mechanisms.

**Conflict of Interest:** None

**Source of Funding:** None

**Declaration of Generative AI and AI-Assisted Technologies in the Writing Process:** None

## References

1. Elendu C, Amaechi DC, Elendu ID, Elendu TC, Amaechi EC, Usoro EU, Chima-Ogbuiyi NL, Agbor DB, Onwuegbule CJ, Afolayan EF, Balogun BB. Global perspectives on the burden of sexually transmitted diseases: A narrative review. *Medicine*. 2024 May 17;103(20):e38199. [Google Scholar] [Pubmed]
2. Serraino R, Cesana BM, Morrone HL, Marino GG, Cirillo M, Olivadese V, Kyambadde P, Biriwo LS, Mutebi F, Treçarichi EM, Musinguzi P. Utility, acceptability and applicability of a nucleic acid amplification test in comparison with a syndromic approach in the management of sexually transmitted diseases at Mulago National Referral Hospital in Uganda (ASTRHA): protocol for an open-label, randomised controlled trial. *BMJ open*. 2024 Jun 1;14(6):e084806. [Google Scholar] [Pubmed]
3. Smeds S, Obern C, Poromaa IS, Westerbergh J, Tydén T, Gyllenberg F. Self-reported sexually transmitted infections and associated risk factors among female university students. *Upsala journal of medical sciences*. 2024 Sep 30;129:10-48101. [Google Scholar] [Pubmed]
4. Chitneni P, Owembabazi M, Muyindike W, Asiimwe S, Masete G, Mbalibulha Y, Nakku-Joloba E, Manabe YC, Haberer JE, Matthews LT, Van Der Pol B. Sexually transmitted infection point-of-care testing in resource-limited settings: a narrative review guided by an implementation framework. *Sexually transmitted diseases*. 2023 Oct 1;50(10):e11-6. [Google Scholar] [Pubmed]
5. Gottlieb SL, Spielman E, Abu-Raddad L, Aderoba AK, Bachmann LH, Blondeel K, Chen XS, Crucitti T, Camacho GG, Godbole S, de Leon RG. WHO global research priorities for sexually transmitted infections. *The Lancet Global Health*. 2024 Sep 1;12(9):e1544-51. [Google Scholar] [Pubmed]
6. Cannovo N, Bianchini E, Gironacci L, Garbati E, Di Prospero F, Cingolani M, Scendoni R, Fedeli P. Sexually Transmitted Infections in Adolescents and Young Adults: A Cross Section of Public Health. *International Journal of Environmental Research and Public Health*. 2024 Apr 19;21(4):501. [Google Scholar]
7. Tuan J, Goheen MM, Trebelcock W, Dunne D. Sexually Transmitted Infections in People with Human Immunodeficiency Virus. *Infectious Disease Clinics*. 2024 Sep 1;38(3):559-79. [Google Scholar] [Pubmed]
8. Balaji S, Bhargava A, Aggarwal S. Emerging and re-emerging sexually transmitted diseases: a review of epidemiological evidences. *Indian journal of sexually transmitted diseases and AIDS*. 2022 Jan 1;43(1):20-6. [Google Scholar] [Pubmed]
9. Orbe-Orihuela YC, Sánchez-Alemán MÁ, Hernández-Pliego A, Medina-García CV, Vergara-Ortega DN. Syphilis as re-emerging disease, antibiotic resistance, and vulnerable population: global systematic review and meta-analysis. *Pathogens*. 2022 Dec 15;11(12):1546. [Google Scholar] [Pubmed]
10. Biswal D, Gupta S, Sethi S, Singh S, Khanna N, Dhawan B. Macrolide and fluoroquinolone resistance associated mutations in *Mycoplasma genitalium* in men who have sex with men attending STI clinic: A pilot study from India. *Indian J Dermatol Venereol Leprol*. 2024 Sep 1;90:632-5. [Google Scholar] [Pubmed]
11. Abavisani M, Keikha M. Global analysis on the mutations associated with multidrug-resistant urogenital mycoplasmas and ureaplasmas infection: a systematic review and meta-analysis. *Annals of Clinical Microbiology and Antimicrobials*. 2023 Aug 10;22(1):70. [Google Scholar] [Pubmed]
12. De Baetselier I, Vuylsteke B, Reyniers T, Smet H, Van den Bossche D, Kenyon C, Crucitti T. Worryingly high prevalence of resistance-associated mutations to macrolides and fluoroquinolones in *Mycoplasma genitalium* among men who have sex with men with recurrent sexually transmitted infections. *International journal of STD & AIDS*. 2022 Mar;33(4):385-90. [Google Scholar] [Pubmed]
13. Giacani L, Bradshaw CS, Muzny CA, Graves KJ, Pasricha S, Jordan SJ, Allan-Blitz LT. Antimicrobial Resistance in Curable Sexually Transmitted Infections. *Current HIV/AIDS Reports*. 2025 Dec;22(1):14. [Google Scholar] [Pubmed]
14. Waltmann A, Thomas C, Duncan JA. The role of the genital microbiota in the acquisition and pathogenesis of sexually transmitted infections. *Current opinion in infectious diseases*. 2023 Feb 1;36(1):35-48. [Google Scholar] [Pubmed]
15. Tuddenham S, Ravel J, Marrazzo JM. Protection and risk: male and female genital microbiota and sexually transmitted infections. *The Journal of infectious diseases*. 2021 Jun 15;223(Supplement\_3):S222-35. [Google Scholar] [Pubmed]
16. Dabee S, Passmore JA, Heffron R, Jaspan HB. The complex link between the female genital microbiota, genital infections, and inflammation. *Infection and immunity*. 2021 Apr 16;89(5). [Google Scholar] [Pubmed]
17. Price LB, Liu CM, Johnson KE, Aziz M, Lau MK, Bowers J, Ravel J, Keim PS, Serwadda D, Wawer MJ, Gray RH. The effects of circumcision on the penis microbiome. *PLoS one*. 2010 Jan 6;5(1):e8422. [Google Scholar] [Pubmed]
18. Gosmann C, Handley SA, Farcasanu M, Abu-Ali G, Bowman BA, Padavattan N, Desai C, Droit L, Moodley A, Dong M, Chen Y. Lactobacillus-deficient cervicovaginal bacterial communities are associated with increased HIV acquisition in young South African women.

- Immunity. 2017 Jan 17;46(1):29-37. [Google Scholar] [Pubmed]
19. Brotman RM. Vaginal microbiome and sexually transmitted infections: an epidemiologic perspective. *The Journal of clinical investigation*. 2011 Dec 1;121(12):4610-7. [Google Scholar] [Pubmed]
  20. Eastment MC, McClelland RS. Vaginal microbiota and susceptibility to HIV. *Aids*. 2018 Mar 27;32(6):687-98. [Google Scholar] [Pubmed]
  21. Kanamori H, Rutala WA, Weber DJ. The role of patient care items as a fomite in healthcare-associated outbreaks and infection prevention. *Clinical Infectious Diseases*. 2017 Oct 15;65(8):1412-9. [Google Scholar] [Pubmed]
  22. Haun N, Hooper-Lane C, Safdar N. Healthcare personnel attire and devices as fomites: a systematic review. *infection control & hospital epidemiology*. 2016 Nov;37(11):1367-73. [Google Scholar] [Pubmed]
  23. Braccio S, Sharland M, Ladhani SN. Prevention and treatment of mother-to-child transmission of syphilis. *Current opinion in infectious diseases*. 2016 Jun 1;29(3):268-74. [Google Scholar] [Pubmed]
  24. Kinikar A, Gupte N, Bhat J, Bharadwaj R, Kulkarni V, Bhosale R, McIntire KN, Mave V, Suryavanshi N, Patil S, Bollinger R. Maternal syphilis: an independent risk factor for mother to infant human immunodeficiency virus transmission. *Sexually transmitted diseases*. 2017 Jun 1;44(6):371-5. [Google Scholar] [Pubmed]
  25. Peters RP, Feucht UD, de Vos L, Ngwepe P, McIntyre JA, Klausner JD, Medina-Marino A. Mother-to-child transmission of *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and *Trichomonas vaginalis* in HIV-infected pregnant women in South Africa. *International journal of STD & AIDS*. 2021 Aug;32(9):799-805. [Google Scholar] [Pubmed]
  26. Honkila M, Wikström E, Renko M, Surcel HM, Pokka T, Ikäheimo I, Uhari M, Tapiainen T. Probability of vertical transmission of *Chlamydia trachomatis* estimated from national registry data. *Sexually Transmitted Infections*. 2017 Sep 1;93(6):416-20. [Google Scholar] [Pubmed]
  27. Nartey YA, Bockarie AS. Mother-to-child transmission of hepatitis B: current status and the road forward. *Nature Reviews Gastroenterology & Hepatology*. 2024 Aug;21(8):531-2. [Google Scholar] [Pubmed]
  28. World Health Organization. Triple elimination initiative of mother-to-child transmission of HIV, syphilis and hepatitis B. Online. 2022. [Google Scholar]
  29. Relhan V, Bansal A, Hegde P, Sahoo B. Sexually transmitted infections in the elderly: A 6-year retrospective study in a tertiary care hospital in New Delhi. *Indian Journal of Sexually Transmitted Diseases and AIDS*. 2021 Jul 1;42(2):144-9. [Google Scholar] [Pubmed]
  30. Van Gerwen OT, Jani A, Long DM, Austin EL, Musgrove K, Muzny CA. Prevalence of sexually transmitted infections and human immunodeficiency virus in transgender persons: a systematic review. *Transgender Health*. 2020 Jun 1;5(2):90-103. [Google Scholar] [Pubmed]
  31. Parekh T, Gimm G, Kitsantas P. Sexually transmitted infections in women of reproductive age by disability type. *American Journal of Preventive Medicine*. 2023 Mar 1;64(3):393-404. [Google Scholar] [Pubmed]
  32. Schmidt EK, Hand BN, Simpson KN, Darragh AR. Sexually transmitted infections in privately insured adults with intellectual and developmental disabilities. *Journal of Comparative Effectiveness Research*. 2019 Jun;8(8):599-606. [Google Scholar] [Pubmed]
  33. Jenkins WD, Williams LD, Pearson WS. Sexually transmitted infection epidemiology and care in rural areas: A narrative review. *Sexually transmitted diseases*. 2021 Dec 1;48(12):e236-40. [Google Scholar] [Pubmed]
  34. Vargas S, Calvo G, Qquellon J, Vasquez F, Blondeel K, Ballard R, Toskin I. Point-of-care testing for sexually transmitted infections in low-resource settings. *Clinical Microbiology and Infection*. 2022 Jul 1;28(7):946-51. [Google Scholar] [Pubmed]
  35. What Do I Need to Know About Nucleic-Acid Amplification Tests? Verywell Health, <https://www.verywellhealth.com/nucleic-acid-amplification-tests-3132631> (accessed 9 April 2025).
  36. Townsend H, Hobbs J, Kaylor S, Cody S, Callihan M. Point-of-care STI testing in rural settings: A feasibility project. *Public Health Nursing*. 2024 Sep;41(5):1202-5. [Google Scholar] [Pubmed]
  37. Riegler AN, Larsen N, Amerson-Brown MH. Point-of-Care Testing for Sexually Transmitted Infections. *Clinics in Laboratory Medicine*. 2023 Jun 1;43(2):189-207. [Google Scholar] [Pubmed]
  38. Bradic M, Warring SD, Tooley GE, Scheid P, Secor WE, Land KM, Huang PJ, Chen TW, Lee CC, Tang P, Sullivan SA. Genetic indicators of drug resistance in the highly repetitive genome of *Trichomonas vaginalis*. *Genome biology and evolution*. 2017 Jun;9(6):1658-72. [Google Scholar] [Pubmed]
  39. Day MJ, Boampong D, Pitt R, Bari A, Rebec M, Saunders J, Fifer H, Mbisa JL, Cole MJ. Molecular detection of ceftriaxone resistance in *Neisseria gonorrhoeae* clinical specimens: a tool for public health control. *Sexually Transmitted Infections*. 2024 Nov 1;100(7):454-6. [Google Scholar] [Pubmed]
  40. Golparian D, Unemo M. Antimicrobial resistance prediction in *Neisseria gonorrhoeae*: current status and future prospects. *Expert Review of Molecular Diagnostics*. 2022 Jan 2;22(1):29-48. [Google Scholar] [Pubmed]
  41. Michibuchi M, Yoshikane T, Matsuba Y, Yamazaki

- T, Hatakeyama S, Takanashi M, Oikawa T, Suzuki H. Development of a New Rapid Simultaneous Molecular Assay for the Detection of STI Pathogens and Drug Resistance-Associated Mutations. *Molecular Diagnosis & Therapy*. 2025 Jan 17;1-0. [Google Scholar] [Pubmed]
42. Gardette M, Hénin N, Le Roy C, Guiraud J, Touati A, Bébéar C, Pereyre S. Clinical performance of three commercial molecular diagnostic assays for the detection of fluoroquinolone resistance-associated mutations in *Mycoplasma genitalium*. *Journal of Clinical Microbiology*. 2022 Dec 21;60(12):e01135-22. [Google Scholar] [Pubmed]
  43. Muralidhar S. Molecular methods in the laboratory diagnosis of sexually transmitted infections. *Indian journal of sexually transmitted diseases and AIDS*. 2015 Jan 1;36(1):9-17. [Google Scholar] [Pubmed]
  44. Tomas ME, Getman D, Donskey CJ, Hecker MT. Overdiagnosis of urinary tract infection and underdiagnosis of sexually transmitted infection in adult women presenting to an emergency department. *Journal of clinical microbiology*. 2015 Aug;53(8):2686-92. [Google Scholar] [Pubmed]
  45. Levy I, Gefen-Halevi S, Nissan I, Keller N, Pilo S, Wieder-Finesod A, Litchevski V, Shasha D, Kedem E, Rahav G. Delayed diagnosis of colorectal sexually transmitted diseases due to their resemblance to inflammatory bowel diseases. *International Journal of Infectious Diseases*. 2018 Oct 1;75:34-8. [Google Scholar] [Pubmed]
  46. Shahesmaeili A, Karamouzian M, Shokoohi M, Kamali K, Fahimfar N, Nadji SA, Sharifi H, Haghdoost AA, Mirzazadeh A. Symptom-based versus laboratory-based diagnosis of five sexually transmitted infections in female sex workers in Iran. *AIDS and Behavior*. 2018 Jul;22:19-25. [Google Scholar] [Pubmed]
  47. Wi TE, Ndowa FJ, Ferreyra C, Kelly-Cirino C, Taylor MM, Toskin I, Kiarie J, Santesso N, Unemo M. Diagnosing sexually transmitted infections in resource-constrained settings: challenges and ways forward. *Journal of the International AIDS Society*. 2019 Aug;22:e25343. [Google Scholar] [Pubmed]
  48. Wong LP, Wong PF, Megat Hashim MM, Han L, Lin Y, Hu Z, Zhao Q, Zimet GD. Multidimensional social and cultural norms influencing HPV vaccine hesitancy in Asia. *Human vaccines & immunotherapeutics*. 2020 Jul 2;16(7):1611-22. [Google Scholar] [Pubmed]
  49. Wong LP. An exploration of knowledge, attitudes and behaviours of young multiethnic Muslim-majority society in Malaysia in relation to reproductive and premarital sexual practices. *BMC public health*. 2012 Dec;12:1-3. [Google Scholar] [Pubmed]
  50. Mwaka AD, Okello ES, Orach CG. Barriers to biomedical care and use of traditional medicines for treatment of cervical cancer: an exploratory qualitative study in northern Uganda. *European journal of cancer care*. 2015 Jul;24(4):503-13. [Google Scholar] [Pubmed]
  51. Wong LP, Wong PF, AbuBakar S. Vaccine hesitancy and the resurgence of vaccine preventable diseases: the way forward for Malaysia, a Southeast Asian country. *Human vaccines & immunotherapeutics*. 2020 Jul 2;16(7):1511-20. [Google Scholar] [Pubmed]
  52. Ladner J, Besson MH, Audureau E, Rodrigues M, Saba J. Experiences and lessons learned from 29 HPV vaccination programs implemented in 19 low and middle-income countries, 2009-2014. *BMC health services research*. 2016 Dec;16:1-0. [Google Scholar] [Pubmed]
  53. Simmons D. The role of ethnography in STI and HIV/AIDS education and promotion with traditional healers in Zimbabwe. *Health promotion international*. 2011 Dec 1;26(4):476-83. [Google Scholar] [Pubmed]
  54. Thomas TL, Yarandi HN, Dalmida SG, Frados A, Klienert K. Cross-cultural differences and sexual risk behavior of emerging adults. *Journal of Transcultural Nursing*. 2015 Jan;26(1):64-72. [Google Scholar] [Pubmed]
  55. Sewak A, Yousef M, Deshpande S, Seydel T, Hashemi N. The effectiveness of digital sexual health interventions for young adults: a systematic literature review (2010–2020). *Health Promotion International*. 2023 Feb 1;38(1):daac104. [Google Scholar] [Pubmed]
  56. Martínez-García G, Ewing AC, Olugbade Y, DiClemente RJ, Kourtis AP. Crush: a randomized trial to evaluate the impact of a Mobile Health App on adolescent sexual health. *Journal of Adolescent Health*. 2023 Feb 1;72(2):287-94. [Google Scholar] [Pubmed]
  57. Chandler R, Guillaume D, Francis S, Xue E, Shah K, Parker A, Hernandez N. "I care about sex, I care about my health": A mixed-methods pre-test of a HIV prevention mobile health app for Black women in the southern United States. *Plos one*. 2023 Oct 18;18(10):e0289884. [Google Scholar] [Pubmed]
  58. Sharma A, Boyd S, Bonar EE. Feasibility and Acceptability of a Motivational Interviewing–Based Telehealth Intervention for Bacterial Sexually Transmitted Infection Screening: Protocol for a Sequential Explanatory Mixed Methods Study. *JMIR Research Protocols*. 2024 Aug 29;13(1):e64433. [Google Scholar] [Pubmed]
  59. Washington RG, Nath A, Isac S, Javalkar P, Ramesh BM, Bhattacharjee P, Moses S. Evaluation of a community-based HIV preventive intervention for female sex workers in rural areas of Karnataka State, south India. *Asia Pacific Journal of Public Health*. 2014 Jul;26(4):349-57. [Google Scholar] [Pubmed]
  60. Rhodes SD, Daniel-Ulloa J, Wright SS, Mann-Jackson L, Johnson DB, Hayes NA, Valentine JA. Critical elements of community engagement to address disparities and

- related social determinants of health: the centers of disease control and prevention community approaches to reducing sexually transmitted disease initiative. *Sexually transmitted diseases*. 2021 Jan 1;48(1):49-55. [Google Scholar] [Pubmed]
61. Valentine JA, Delgado LF, Haderxhanaj LT, Hogben M. Improving sexual health in US rural communities: reducing the impact of stigma. *AIDS and Behavior*. 2022 Jan;26(Suppl 1):90-9. [Google Scholar] [Pubmed]
62. Tibbits M, Siahpush M. Implementation of sexually transmitted infection interventions: Insights from a community-wide assessment. *Health promotion practice*. 2017 Mar;18(2):290-7. [Google Scholar] [Pubmed]
63. Park S, Russo R, Westfall L, Shrestha R, Zimmerman M, Dartois V, Kurepina N, Kreiswirth B, Singleton E, Li SG, Mittal N. A novel oral GyrB/ParE dual binding inhibitor effective against multidrug-resistant *Neisseria gonorrhoeae* and other high-threat pathogens. *Antimicrobial agents and chemotherapy*. 2022 Sep 20;66(9):e00414-22. [Google Scholar] [Pubmed]
64. Unemo M, Golparian D, Eyre DW. Antimicrobial resistance in *Neisseria gonorrhoeae* and treatment of gonorrhea. *Neisseria gonorrhoeae: methods and protocols*. 2019:37-58. [Google Scholar] [Pubmed]
65. Raccagni AR, Ranzenigo M, Bruzzesi E, Maci C, Castagna A, Nozza S. *Neisseria gonorrhoeae* antimicrobial resistance: the future of antibiotic therapy. *Journal of Clinical Medicine*. 2023 Dec 18;12(24):7767. [Google Scholar] [Pubmed]
66. Williams E, Fairley CK, Williamson D. Novel strategies for prevention and treatment of antimicrobial resistance in sexually-transmitted infections. *Current Opinion in Infectious Diseases*. 2021 Dec 1;34(6):591-8. [Google Scholar] [Pubmed]
67. Stangl AL, Earnshaw VA, Logie CH, Van Brakel W, C. Simbayi L, Barré I, Dovidio JF. The Health Stigma and Discrimination Framework: a global, crosscutting framework to inform research, intervention development, and policy on health-related stigmas. *BMC medicine*. 2019 Dec;17:1-3. [Google Scholar] [Pubmed]
68. Noor MN, Shaw S, Linton J, Lorway R. Barriers to sexual health care for sexually diverse Muslim men: a scoping review. *Sexual Health*. 2024 May 20;21(3). [Google Scholar] [Pubmed]
69. Bohren MA, Corona MV, Odiase OJ, Wilson AN, Sudhinaraset M, Diamond-Smith N, Berryman J, Tunçalp Ö, Afulani PA. Strategies to reduce stigma and discrimination in sexual and reproductive healthcare settings: a mixed-methods systematic review. *PLOS Global Public Health*. 2022 Jun 15;2(6):e0000582. [Google Scholar] [Pubmed]
70. Garcia PJ, Miranda AE, Gupta S, Garland SM, Escobar ME, Fortenberry JD. The role of sexually transmitted infections (STI) prevention and control programs in reducing gender, sexual and STI-related stigma. *EClinicalMedicine*. 2021 Mar 1;33. [Google Scholar] [Pubmed]
71. Schweitzer AM, Dišković A, Krongauz V, Newman J, Tomažič J, Yancheva N. Addressing HIV stigma in healthcare, community, and legislative settings in Central and Eastern Europe. *AIDS research and therapy*. 2023 Dec 11;20(1):87. [Google Scholar] [Pubmed]
72. Singh S, Singh SK. Psychological health and well-being in patients with sexually transmitted infections: A prospective cross-sectional study. *Indian Journal of Sexually Transmitted Diseases and AIDS*. 2021 Jul 1;42(2):125-31. [Google Scholar] [Pubmed]
73. Bretz LA, Keshwani N, Raphael M. Relationship between mental health diagnoses and sexually transmitted infections. *Bulletin of the Menninger Clinic*. 2023 Jun;87(2):115-34. [Google Scholar] [Pubmed]
74. Davis A, Roth A, Brand JE, Zimet GD, Van Der Pol B. Coping strategies and behavioural changes following a genital herpes diagnosis among an urban sample of underserved Midwestern women. *International journal of STD & AIDS*. 2016 Mar;27(3):207-12. [Google Scholar] [Pubmed]
75. Gao Y, MacDonald D, Collins KD, Alaghebandan R, Chen Y. Role of social support in the relationship between sexually transmitted infection and depression among young women in Canada. *Journal of epidemiology*. 2010 Jul 5;20(4):313-8. [Google Scholar] [Pubmed]
76. Suresh R. Temperature effects on prevalence of sexually transmitted infections among at-risk female sex workers in India. [Google Scholar]
77. Logie CH, Toccalino D, Reed AC, Malama K, Newman PA, Weiser S, Harris O, Berry I, Adedimeji A. Exploring linkages between climate change and sexual health: a scoping review protocol. *BMJ open*. 2021 Oct 1;11(10):e054720. [Google Scholar] [Pubmed]
78. Burns PA, Mutunga C. Addressing the impact of climate change on sexual and reproductive health among adolescent girls and young women in low-and middle-income countries. *Global Health: Science and Practice*. 2024 Feb 28;12(1). [Google Scholar] [Pubmed]
79. Arunda MO, Sorcher R, Canabarro AP, Svallfors S, Endler M, Gemzell-Danielsson K, Kågesten A, Ali M, Bahamondes L, Barreix M, Chou D. Climate change and sexual and reproductive health and rights research in low-income and middle-income countries: a scoping review. *BMJ Public Health*. 2024 Aug 24;2(2). [Google Scholar] [Pubmed]
80. Logie CH, Toccalino D, MacKenzie F, Hasham A, Narasimhan M, Donkers H, Lorimer N, Malama K.

- Associations between climate change-related factors and sexual health: a scoping review. *Global public health*. 2024 Dec 31;19(1):2299718. [Google Scholar] [Pubmed]
81. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee on Prevention and Control of Sexually Transmitted Infections in the United States. *Sexually Transmitted Infections: Adopting a Sexual Health Paradigm*. Crowley JS, Geller AB, Vermund SH, editors. Washington (DC): National Academies Press (US); 2021 Mar 24. PMID: 34432397. [Pubmed]
  82. Gimenes F, Souza RP, Bento JC, Teixeira JJ, Maria-Engler SS, Bonini MG, Consolaro ME. Male infertility: a public health issue caused by sexually transmitted pathogens. *Nature Reviews Urology*. 2014 Dec;11(12):672-87. [Google Scholar] [Pubmed]
  83. Li S, Wang M, He M, Xu Y, Li C, Huang Y, Tao X. MicroRNAs as Potential Biomarkers for the Diagnosis, Treatment, and Prognosis of Sexually Transmitted Diseases: Recent Advances and Future Directions. *Dermatologic Therapy*. 2024;2024(1):7835561. [Google Scholar]
  84. Li C, Zhao P, Tan RK, Wu D. Community engagement tools in HIV/STI prevention research. *Current Opinion in Infectious Diseases*. 2024 Feb 1;37(1):53-62. [Google Scholar] [Pubmed]
  85. Sanz-Lorente M, Wanden-Berghe C, Castejón-Bolea R, Sanz-Valero J. Web 2.0 tools in the prevention of curable sexually transmitted diseases: scoping review. *Journal of medical Internet research*. 2018 Mar 22;20(3):e8871. [Google Scholar] [Pubmed]